Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Weinhold, Niels  [Clear All Filters]
2024
Salwender H, Weinhold N, Benner A, Miah K, Merz M, Haenel M, Jehn C, Mai E, Menis E, Blau I, et al. Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial. Hematology. 2024;29(1):2320006.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, et al. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial. Lancet Haematol. 2024;11(2):e101-e113.
Maura F, Rajanna ARaj, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024:JCO2301277.
2023
Stelmach P, Richter S, Sauer S, Fabre MA, Gu M, Rohde C, Janssen M, Liebers N, Proynova R, Weinhold N, et al. Clonal hematopoiesis with and mutations impairs regeneration in autologous stem cell transplant recipients. Haematologica. 2023.
Kauer J, Sester LSophie, Kriegsmann K, Weinhold N, Ober M, Müller-Tidow C, Goldschmidt H, Raab M-S, Sauer S. Cyclophosphamide etoposide dexamethasone (CED) as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematol Oncol. 2023.
Zhao D, Rohde C, Göllner S, Zhou F, Pauli C, Blank MFelix, Zinz R, Grab ALuise, Poos AM, John L, et al. The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations. Leukemia. 2023.
Kauer J, Freundt EP, Schmitt A, Weinhold N, Mai EK, Müller-Tidow C, Goldschmidt H, Raab MS, Kriegsmann K, Sauer S. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer. 2023;23(1):1132.
2022
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase . Lancet Haematol. 2022;9(11):e810-e821.
2019
Sridharan A, Schinke CD, Georgiev G, Ferreira MDa Silva, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, et al. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Adv. 2019;3(23):3962-3967.
2018
Holstein SA, J Ye C, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, C Landgren O, Munshi NC, et al. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant. 2018.